Arkolith/Insider Trading/NVCT/Form 4

Bentsur Ron

Chairman & CEO, Director, 10% OwnerNuvectis Pharma, Inc. (NVCT) · full profile →Form 4 · filed Nov 6, 2025
Net Buying
Open-Market Buys
$29K
Open-Market Sells
$0
Net Open-Market Flow
$29K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 5, 2025Buy(P)5K$5.72$29K3.5M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-107423) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML